Biotech Values

[mcbio]

Victoza bests Lyxumia in head-to-head trial, says NVO:

Key questions for me on this are:

1. Are they using a proper comparative dose of Lyxumia or using lower than typical dose to make Victoza results look better (or some other reason)?

2. More specifically, how does Victoza and Lyxumia doses used in study compare to dose of those drugs used as part of the Xultophy and LixiLan combos, respectively?

3. Even if no issues on the aforementioned, and we assume this data would roughly carry over to any comparison of the combo drugs that contain each drug, how material an advantage overall would this give Xultophy over LixiLan? Could LixiLan still carve out a meaningful share of the market?